安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell . . .
Background: To review and discuss the literature on applying tyrosine kinase inhibitors (TKIs) in the treatment of metastasised renal cell carcinoma (mRCC) Materials and Methods: Medline, PubMed, the Cochrane database, and Embase were screened for randomised controlled trials, clinical trials, and reviews on treating renal cell carcinoma, and
- Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A . . .
Multiple large clinical trials have investigated adjuvant tyrosine kinase inhibitors (TKIs) to reduce the risk of cancer recurrence and progression to metastasis in high-risk renal cell carcinoma We sought to maintain living and interactive evidence on this topic, until a high level of certainty is reached for key clinical outcomes such that
- IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A . . .
Multiple systemic immune-oncology (IO) combination therapies have demonstrated overall survival (OS) benefits in metastatic renal clear cell carcinoma (mRCC) However, the magnitude of benefits over time has not been compared in a structured fashion To assess OS and progression free survival (PFS) …
- First and Second-line Treatments in Metastatic Renal Cell Carcinoma
First-line treatment for metastatic renal cell carcinoma combines an anti-PD1 antibody with either an anti-CTLA4 antibody or an antiangiogenic tyrosine kinase inhibitor (TKI) Treatment selection depends on factors such as performance status and risk Second-line options include antiangiogenic TKIs, mTOR inhibitors, and HIF2A inhibitors; the evidence does not support immunotherapy rechallenge
- Evaluating Patient Adherence and Persistence to Tyrosine-Kinase . . .
In the United States, there are approximately 82 000 new cases of renal cell carcinoma (RCC) and almost 15 000 deaths from RCC each year 1 Between 75% and 85% of RCCs exhibit a clear cell histology, with less common subtypes including papillary, chromophobe, and medullary Systemic therapy options for those patients with relapsed or stage 5 disease are largely comprised of oral targeted
- Reviewing RCC Treatment Choices After Progression With IO TKI
During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO TKI combinations plus VEGF selectivity Decrease or stabilization in metastatic lesions noted on follow-up imaging He tolerated therapy well, with 1 interruption due to hypothyroidism on
- Update on systemic therapy for clear cell renal cell carcinoma
The treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 years later, both demonstrating significantly improved overall survival (OS) rates across all RCC risk categories Currently, combination therapies
- Resistance to tyrosine kinase inhibitors promotes renal cancer . . .
Tyrosine kinase inhibitors (TKIs) are the most commonly used targeted therapeutics in clear-cell renal cell carcinoma (ccRCC); however, drug resistance limits their utility and can lead to tumor
|
|
|